drug pricing reform

Statement of John Conrad, President & CEO, Illinois Biotechnology Innovation Organization (iBIO) On the Passage of HB 4327 and HB 2371

by John Conrad | Jun 1, 2026 | iBIO News, Policy News

The passage of HB 4327 is a significant and long-overdue win for transparency, accountability, and — most importantly — for Illinois patients. For the first time, Illinois will have an independent, standardized accounting of how the 340B program actually operates in...

iBIO Statement on Illinois CMS Memo: State’s Own Analysis Shows 340B Expansion Would Add Hundreds of Millions in Costs Without Evidence of Patient Savings

by John Conrad | May 15, 2026 | Policy News

CHICAGO — The Illinois Biotechnology Innovation Organization (iBIO) today responded to a May 12, 2026 memorandum from the Illinois Department of Central Management Services (CMS) — the state agency that administers the State Employees Group Insurance Program (SEGIP) —...

What MFN Would Cost Illinois

by John Conrad | May 13, 2026 | Policy News

As Congress debates Most Favored Nation (MFN) drug pricing — a policy that would peg Medicare drug prices to rates paid in other high-income countries — two new reports put the stakes in sharp relief. The picture for patients and for Illinois is not a good one. A new...